PRX019
Alzheimer's Disease
Key Facts
About Prothena
Prothena Corporation plc is a Nasdaq-listed biotech firm focused on discovering and developing transformative antibody therapies for diseases driven by protein misfolding, including Parkinson's disease and ATTR amyloidosis. The company's strategy is built upon a foundational scientific legacy from Athena Neurosciences and Elan, which has yielded key discoveries in amyloid biology and led to commercial products like Tysabri. Prothena advances a mix of wholly-owned and partnered clinical-stage assets, targeting high-need neurological and rare disease markets with significant unmet medical need. Its core competency lies in designing antibodies that selectively target pathogenic forms of proteins to modify disease progression.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |